Summary
Serum iron, total iron binding capacity and ferritin was estimated in 42 patients with early Huntington disease (HD) and in 148 matched controls. Ferritin levels were significantly low in affected male subjects as compared to controls. Iron levels and total iron binding capacity were normal in HD patients. The importance of this finding, that occurs early in the pathogenesis of HD, is unknown. Correspondence to: Dr. Morrison.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jacobs, A. Iron metabolism. In Wetherall.D. J.,Ledingham, J. G. G., Warrell, D. A. (eds). Oxford Textbook of Medicine. Oxford University Press. 1990. Chapter 19.
Papadopolous, P., Bhavsar, D., Zappone, E., David, V., Jones, C., Worwood, M., Drysdale, J. A second human ferritin H locus on chromosome 11. Cytogenet Cell Genet. 1992: 61, 107–108.
Klintworth, G.K. Cerebral iron deposition in Huntington’s disease, Proceedings of the Second International Congress of Neurogenetics and Neuro-opthalmology of the World Federation of Neurology, Montreal, Canada 1967: p42.
Strassman, G. Iron and calcium deposits in the brain: their pathological significance. J. Neuropath. Exp. Neurol. 8 1949: 428.
Goldberg, W. J., Allen, N. Determinations of Cu, Mn, Fe and Ca in six regions of normal human brain, by atomic absorption spectroscopy. Clin. Chem. 1981: 27, 562–564.
Bonilla, E., Estevez, J., Suarez, H., Morales, L. M., Chacin de Bonilla, L., Villalobos, R., Davila, J. O. Serum ferritin deficiency in Huntington’s disease patients. Neurosci. Lett. 1991: 129, 22–24.
Morrison, P. J. The epidemiology and genetics of Huntington’s Disease. MD Thesis, The Queen’s University of Belfast. 1993.
Suarez, H., Cimino, F., Bonilla, E. Hierro en el sistema nervioso central. Metabolismo y consideraciones fisiopatologicas, revision. Invest. Clin. 1985: 247–322.
Garrett, M. C., Soares-da-Silva, P. Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington’s disease: evidence for an overactive dopaminergic brain transmission. J. Neurochem. 1992: 58, 101–106.
Harris, G. J., Pearlson, G. D., Peyser, C. E., Aylward, E. H., Roberts, J., Barta, P. E., Chase. G. A., Folstein, S. E. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington’s disease. Ann. Neurol. 1992: 31, 69–75.
Morales, L. M., Estevez, J., Suarez, H., Villalobos, R., Chacin de Bonilla, L., Bonilla, E. Nutritional evaluation of Huntington’s disease patients. Am. J. Clin. Nutr. 1989: 50, 145–150.
Morrison, P. J. Trinucleotide repeat repeat repeat. Lancet 1993: 342, 385–386.
The Huntington’s Disease Collaborative research group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993: 72, 971–983.
Dexter, D. T., Carayon, A., Vidailhet, M., Ruberg, M., Agid, F., Agid, Y., Lees, A. J., Wells, F. R., Jenner, P., Marsden, C. D. Decreased ferritin levels in brain in Parkinson’s Disease. J. Neurochem. 1990: 55, 16–20.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, P.J., Nevin, N.C. Serum iron, total iron binding capacity and ferritin in early huntington disease patients. I.J.M.S. 163, 236–237 (1994). https://doi.org/10.1007/BF02943258
Issue Date:
DOI: https://doi.org/10.1007/BF02943258